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Background: Vitamin D deficiency is a re-emerging epidemic, especially in minority populations. Vitamin D is
crucial not only for bone health but for proper brain development and functioning. Low levels of vitamin D are
associated with depression, seasonal affective disorder, and schizophrenia in adults, but little is known about
vitamin D and mental health in the pediatric population.
Methods: One hundred four adolescents presenting for acute mental health treatment over a 16-month period
were assessed for vitamin D status and the relationship of 25-OH vitamin D levels to severity of illness, defined by
presence of psychotic features.
Results: Vitamin D deficiency (25-OH D levels <20 ng/ml) was present in 34%; vitamin D insufficiency (25-OH D
levels 20–30 ng/ml) was present in 38%, with a remaining 28% in the normal range. Adolescents with psychotic
features had lower vitamin D levels (20.4 ng/ml vs. 24.7 ng/ml; p = 0.04, 1 df). The association for vitamin D
deficiency and psychotic features was substantial (OR 3.5; 95% CI 1.4-8.9; p <0.009). Race was independently
associated with vitamin D deficiency and independently associated with psychosis for those who were Asian or
biracial vs. white (OR = 3.8; 95% CI 1.1-13.4; p< 0.04). Race was no longer associated with psychosis when the results
were adjusted for vitamin D level.
Conclusions: Vitamin D deficiency and insufficiency are both highly prevalent in adolescents with severe mental
illness. The preliminary associations between vitamin D deficiency and presence of psychotic features warrant
further investigation as to whether vitamin D deficiency is a mediator of illness severity, result of illness severity, or
both. Higher prevalence of vitamin D deficiency but no greater risk of psychosis in African Americans, if confirmed,
may have special implications for health disparity and treatment outcome research.
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Vitamin D deficiency is endemic across the life span and
in diverse populations throughout the world [1].
Contributing factors are lack of exposure to sunlight and
insufficient dietary intake; individuals with darker skin
are at higher risk due to low cutaneous synthesis and
dairy-poor diets. In a study of healthy Northeastern US
adolescents, more than 90% of African American teens
and 55% of all teens had low vitamin D [2]. The National
Health and Nutritional Examination Survey (NHANES* Correspondence: Barbara.gracious@nationwidechildrens.org
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reproduction in any medium, provided the or2001–2004) found an overall US prevalence of vitamin D
insufficiency in adolescents of 61%, with 9% deficient [3].
Vitamin D is well recognized as essential for intestinal cal-
cium absorption, serum calcium homeostasis, optimal skel-
etal development, and the prevention of rickets and
osteoporosis [4]. The importance of vitamin D to the CNS
in both healthy and psychiatric populations is less well-
appreciated and is vastly understudied compared to its
known impact on bone health. Vitamin D receptors are
present throughout the brain, and D-deficiency is associated
with negative CNS effects in animal studies [5]. Vitamin D
receptors and activating enzymes are particularly prominent
in the hypothalamus and substantia nigra, and are involved
in glucocorticoid signaling in hippocampal cells. Depletion
models show maternal offspring with abnormal brain shape,
cell number, and reduced neurotropic factors and receptors.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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increased anxiety, decreased activity, and muscular and
motor impairments, resembling phenotypic models of de-
pression. Vitamin D is neuroprotective to hippocampal
cells, through regulating calcium ion channels and activat-
ing PKC and mapPK pathways.
Clinical studies reinforce the significance of this basic
work. A Finnish cohort supplemented with prenatal and
infant vitamin D demonstrated reduced adult risk for
schizophrenia [6]. Low vitamin D levels were found to
correlate with major depression [7] and premenstrual
mood symptoms in women [8], and mood disorders and
cognitive impairment in older adults [9]. Two rando-
mized controlled trials (RCT) have shown that raising
vitamin D levels improved depression. The first study
examined phototherapy vs. vitamin D supplementation
for seasonal affective disorder, and found a positive effect
for vitamin D via either supplementation or phototherapy
within one month [10]. Another RCT of overweight and
obese subjects, at greater risk for low vitamin D than
those of normal weight, found higher levels of depression
with low vitamin D; supplementation resulted in signifi-
cant improvement in depressive symptoms after one year
[11]. To the best of our knowledge, there have been no
published studies examining vitamin D deficiency and
the presence of psychosis in adolescents.
We hypothesized that, in severely mentally ill adoles-
cents, defined as adolescents requiring either inpatient
or partial hospitalization, 1) rates of vitamin D insuffi-
ciency and deficiency would be greater than those docu-
mented in general US populations, and 2) lower vitamin
D levels would be associated with mental illness severity,
defined as presence of psychotic features.Methods and Materials
Ethics
The University of Rochester Research Subject Review
Board approved the retrospective chart review study.Participants
The study population included 75 females and 29 males
aged 12 to 18 years admitted to the Strong Behavioral
Health Child and Adolescent Acute Inpatient Service or
Partial Hospitalization Service (CAPHS), Department of
Psychiatry, University of Rochester, NY, between October
2008-February 2010 who had serum 25-OH vitamin D
levels collected on routine admission laboratory testing
as part of a quality improvement initiative.Data collection
Charts were identified by a clinical admission database of
the service. Diagnostic evaluations and symptom reports
from parents/legal guardians and adolescents wereextracted from medical records for the period of clinical
care.
Clinical diagnoses
Clinical DSM-IV diagnoses were predominantly affective
disorders (bipolar disorders, N = 37; depressive disorders,
N = 36; mood disorder NOS, N= 15; psychotic disorders,
N = 8; anxiety disorders, N = 4; and ADHD/ODD N=1).
Patient-reported psychosis and potentially related
variables
Psychotic symptoms, defined as hallucinations, para-
noia, or delusions, were documented on standardized
admission assessment forms by the emergency room
psychiatrist and the admitting attending. They were
categorized dichotomously as yes/no by the second
author (TLF), who was blinded to both the purpose of
the study and to vitamin D levels until after record ex-
traction was completed. Other variables examined
included: race, month of admission/vitamin D level, in-
surance status, urban/suburban/rural residence,
inpatient/partial hospital outpatient, clinical DSM-IV
diagnosis, smoking status, age of onset of mental ill-
ness, admitting medications, past medications, and im-
mediate and extended family psychiatric and medical
history.
Vitamin D laboratory analysis and categorical definitions
Vitamin D 25-OH (25OHD) levels were analyzed by
chemiluminescent immunoassay at ARUP laboratories,
SLC, Utah, and recorded as normal if >30 ng/ml, insuffi-
cient if 20–30 ng/ml, and deficient if <20 ng/ml, as per
expert guidelines [12].
Statistical analyses
Continuous data were graphically inspected for distribu-
tional assumptions; comparisons between the normal, in-
sufficient, and deficient vitamin D groups were evaluated
by ANOVAs (with t-tests subsequent to the overall
analysis), Wilcoxon rank sum test, χ², or Fisher’s exact
test, as appropriate to the data. The relationship of vita-
min D levels and psychosis was assessed with an
ANOVA type design and the association of psychosis
with vitamin D level groups with logistic regression mod-
els, assessing race as well as vitamin D level groups in a
multivariate model. All analyses were carried out using
SAS 9.2 on a Windows 7 platform.
Results
Vitamin D deficiency prevalence and association with
psychosis
Thirty-five (33.7%) adolescents were vitamin D deficient
(<20 ng/ml), and an additional 40 (38.4%) were vitamin
D insufficient (20–30 ng/ml). Of those with vitamin D
Table 1 Patient Characteristics by 25-OH Vitamin D Levels
All N = 104 Deficient
(<20 ng/




























































Body Mass Index (BMI) 25.2 ± 7.6 26.1 ± 8.4 24.7 ± 7.2 0.39
Glucose 93.9 ± 18.1 91.7 ± 13.8 94.9 ± 19.7 0.42
Cholesterol, total 167.4 ± 34.4 167.6 ± 30.8 167.3 + 36.7 0.98
High Density
Lipoprotein (HDL)
53.1 ± 13.9 54.3 ± 13.5 52.4 ± 14.3 0.63
Low Density
Lipoprotein (LDL)
94.0 ± 25.0 95.7 ± 21.9 93.0 ± 26.8 0.71
Triglycerides 96.0 ± 69.3 87.6 ± 57.6 100.5 ± 75.2 0.52
Pulse 79.6 ± 15.6 78.4 ± 12.4 80.3 ± 16.7 0.57
Diastolic Blood Pressure 67.6 ± 9.0 69.1 ± 9.3 66.7 ± 8.7 0.20
Systolic Blood Pressure 115.3 ± 12.7 116.9 ± 14.3 114.5 ± 11.9 0.39
Illness Features
and Family History
Psychosis N, (%) 25 (24.0) 14 (40.0) 11 (15.9) 0.007
Immediate Family
Psychosis N, (%)
10 (9.6) 4 (11.4) 6 (8.7) 0.66
Extended Family
Psychosis N, (%)





45/55 (45) 14 (41.2) 31 (47.0) 0.69
DSM-IV diagnoses,
N (%)
Bipolar Disorders 37 (36) 13 (37) 24 (34.8) 0.81
Unipolar Depressive 36 (35) 9 (25.7) 27 (39.1) 0.17
Mood Disorder NOS 15 (14) 6 (17.1) 9 (13.0) 0.57
Anxiety Disorder NOS 5 (5) 2 (5.7) 3 (4.3) 0.76
Psychotic Disorder NOS 8 (7.7) 5 (14.3) 3 (4.3) 0.07
Other (Yes/No) (%Yes) 3 (1.3) 0 (0.0) 3 (4.3) 0.21
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16% of the sample who were not vitamin D deficient (p
< 0.007). Those with D deficiency were 3½ times more
likely to have psychotic features (OR 3.52, CI 1.38-8.95,
1df ). Of those with normal vitamin D status, 79%
(N= 23/29) did not have psychotic features.
Demographic and other related variable differences
A comparison of demographic variables between adoles-
cents with insufficient, deficient, and normal 25-OH D
levels is presented in Table 1.
Racial differences
Those who were deficient were more likely to be black
or Asian (Figure 1) and have psychotic features
(Figure 2). Figure 3 displays the association of 25-OH
vitamin D and the interaction of race and psychosis. All
groups showed lower 25-OH D levels in the presence of
psychosis including Asians who were all deficient. Asian
(N= 5) and biracial (N= 7) categories were combined
into the “Other” category and Hispanic/Latino ethnicity
(N= 1) was combined with Caucasian in the linear mod-
eling that was conducted. Odds ratio comparisons for
presence of psychosis with vitamin D deficiency as well
as potential covariates, including race and medication
exposure, are depicted in Table 2. Psychosis was inde-
pendently related to race for the “other” group (Asian
and biracial individuals) vs. white group, but not for
black vs. white groups, nor significantly associated for
other vs. blacks. The association of psychosis and vita-
min D level was significant overall in the univariate and
multivariable analyses. Of added interest was the associ-
ation of psychosis with Vitamin D levels and race
(Table 3). While race and vitamin D levels were asso-
ciated, race and psychosis were not associated adjusting
for vitamin D levels.
Family history, medication exposure, and seasonal
differences
Immediate family history of psychosis and current anti-
depressant exposure were also independently related to
psychosis. Rates of vitamin D insufficiency and deficiency
rose from December through March, peaking in March,
as would be expected. No seasonal effects, however, were
statistically detected (p = 0.14), possibly due to both lati-
tude and high rates of overall deficiency and
insufficiency.
Discussion
This is the first report of an association between vitamin
D deficiency in adolescents and severity of mental illness,
defined as presence of psychotic features. These findings
are similar to a cross-sectional study also linking vitamin
D deficiency and adult psychosis [13]. In a study of over




Stimulants N, (%) 6 (5.8) 2(5.7) 4 (5.8) 0.99
Antidepressants N, (%) 44 (42.3) 11 (31.4) 33 (47.8) 0.11
Antipsychotics N, (%) 35 (33.7) 12 (34.3) 23 (66.7) 0.92
Anticonvulsants N, (%) 18 (17.3) 5 (14.9)) 13 (18.8) 0.56
Benzodiazepines N, (%) 6 (5.8) 3 (8.6) 3 (4.35) 0.38
Other medications 31 (29.8) 8 (22.9) 23 (33.3) 0.27
Past Medication
Exposure, N (%)
Stimulants N, (%) 18 (17.3) 7 (20.0) 11 (15.9) 0.60
Antidepressants N, (%) 42 (40.4) 12 (34.3) 30 (56.5) 0.37
Antipsychotics N, (%) 21 (20.2) 6 (17.1) 15 (21.7) 0.58
Anticonvulsants N, (%) 20 (19.2) 4 (11.4) 16 (23.2) 0.15
Benzodiazepines N, (%) 3 (2.88) 0 (0.0) 3 (4.35) 0.21
Other medications 9 (8.7) 2 (5.7) 7 (10.1) 0.4
*Evaluated by ANOVA, Wilcoxon rank sum test, χ², or Fisher’s exact test.
Missing data were present for the following (N): BMI, 4;, glucose 5; cholesterol
and HDL 50; LDL 49;
TG 49, pulse 4, DBP and SBP 5; calcium 6; height 4; waist circumference 50;
weight 3.
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evaluation of severe mental illness and a population-
based sample from the Oslo Health Study, vitamin D
levels and presence of psychosis were compared between
native Norwegians and dark-complexion immigrants to
Norway. Prevalence of vitamin D deficiency and insuffi-
ciency in immigrants with psychosis was 80%, similar to
the 72% in our sample of severely mentally ill adolescents.
Additionally, 43% of the Oslo community populationFigure 1 Box-Whisker plot of vitamin D levels by race.with psychosis met criteria for vitamin D deficiency, also
similar to the 40% of this teen sample with psychosis. In
the adult epidemiologic sample, disorientation on the
PANSS, weight loss, and lack of physical energy corre-
lated with lower 25-OH D levels after controlling for
major depression. Demographics, level of functioning,
lifestyle habits, and BMI were not associated with vitamin
D levels.
Our findings also agree with an unpublished 2011
report of a child and adolescent psychiatric population
residing in the Pacific Northwest. Using the same defini-
tions of deficiency, insufficiency, and normal ranges as in
the current study, 21% of 67 youth with severe psychi-
atric symptoms residing in 2 Oregon residential treat-
ment programs had vitamin D deficiency, vs. 14% of a
comparable NHANES sample. For the children with
psychotic disorders, the prevalence of vitamin D defi-
ciency was 43% [14]. The overall mean 25-OH D level
was 28.9 ng/mL, with 2/3 of the patients falling below
the normal range; mean 25-OHD in the youth with
psychotic disorders was 26.47 ng/mL (SD12.42). Another
group of psychiatric inpatient Parisian adolescents
(N= 136) were also found to be largely vitamin D-
deficient (72.4%), with the mean 25-OHD value 15–
16 ng/mL, lower in blacks and North Africans [15]. No
differences in mean levels were found between those tak-
ing or not taking antipsychotics, indicating that antipsy-
chotics may not lower vitamin D absorption.
The prevalence of vitamin D deficiency in our sample
of acutely mentally ill adolescents is also greater than the
high rates observed in U.S. community adolescent popu-
lations (34% vs. NHANES 9%)[3] and in Australian adult
private psychiatric inpatients (vitamin D deficiency 11%,
Figure 2 Box-Whisker plot of vitamin D levels by psychosis.
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study found a 29% difference between mean levels in
patients vs. controls. Our higher prevalence rates of defi-
ciency and insufficiency may be in part due to the latitude
of Rochester, NY, 43.145 degrees N. Paris, France is
48.51 N, and Geelong, Australia 38.10 S. Except during
summer months, skin makes negligible vitamin D from
sunlight at latitudes above 37 degrees north or below 37
degrees south.Figure 3 Association of psychosis, race, and interaction of psychosis a
displays 25OH-D levels in ng/mL; left vs. right side of figure denotes meanPotential causal mechanisms
Basic and preclinical animal studies provide clues as to
how vitamin D may lower risk for psychosis, and how
vitamin D deficiency may raise risk for psychosis and de-
pression. These mechanisms include 25-OH vitamin D
and calciferol, the renal metabolite of 25-OH D (1,25-
OH D): 1) altering neurotrophic factors and monoamine
levels [17,18], resulting in vitamin D-related behavioral
phenotypes similar to those for depression and psychosisnd race on vitamin D level expressed as continuous data. Y-axis
25OHD levels without and with psychosis by race.






Age } 0.91 (0.69, 1.20) 0.51




BMI } 0.99 (0.94, 1.06) 0.88
CHOL } 0.99 (0.96, 1.01) 0.23
Calcium } 1.70 (0.53, 5.46) 0.38
DBP } 1.01 (0.96, 1.06) 0.73
GLU } 1.02 (0.99, 1.05) 0.07
HDL } 0.98 (0.93, 1.03) 0.40
LDL } 0.99 (0.97, 1.02) 0.71
Pulse } 1.00 (0.97, 1.03) 0.88
SBP } 0.99 (0.96, 1.03) 0.81
Trigl } 0.99 (0.97, 1.01) 0.23
Gender Female vs. Male 0.60 (0.23, 1.58) 0.30
Extended Family Psychosis 2.32 (0.60, 8.99) 0.22
Immediate Family Psychosis 5.92 (1.52,
23.11)
0.01
Onset at Adolescence vs. Prepuberty 1.78 (0.68, 4.68) 0.24
Living in Urban vs. Rural/Suburban
setting
1.40 (0.33, 5.89) 0.64
Inpatient vs. Outpatient Status 1.22 (0.77, 3.12) 0.69
Private Insurance vs. Medicaid 0.45 (0.18, 1.13) 0.09
Race 0.16
Black vs. White 0.95 (0.24, 3.79) 0.95
Other vs. White ** 3.81 (1.08,13.42)0.04





Antipsychotics 1.44 (0.57, 3.70) 0.44
Anticonvulsants 0.88 (0.26, 2.98) 0.84
Benzodiazepines 0.62 (0.03, 4.08) 0.67
Other Medications 0.89 (0.33, 2.41) 0.82
Past Medication
Antidepressants 1.22 (0.49,,3.02) 0.67
Antipsychotics 1.81 (0.63, 5.14) 0.27
Anticonvulsants 1.07 (0.35, 3.30) 0.91
Benzodiazepines 6.78 (0.59, 78.15) 0.13
Other Medications 0.89 (0.17,,4.61) 0.89
Stimulants 0.58 (0.15, 2.20) 0.43
Bolded text denotes significance at p< 0.05.
*Odds ratios greater than one indicates increased odds of psychosis.
} Odds ratio is expressed for a unit increase in the independent variable.
** Other includes Asian and Biracial.
† Current Stimulants evidenced 0 cell count which resulted in questionable
model fit.
Table 3 Multiple regression model (adjusted) for
association of subject characteristics and psychosis
Variable Odds Ratio 95% CI P-Value
Vitamin D Levels
Deficient vs Not Deficient 3.26 (1.15 9.19) 0.03
Race 0.33
Black vs. White 0.59 (0.14, 2.6) 0.49
Other vs. White ** 1.68 (0.52, 7.67) 0.27
Other vs. Black 3.65 (0.64, 20.83) 0.14
*Odds ratios greater than one indicates increased odds of psychosis.
** White includes Hispanic; Other includes Asian and Biracial.
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changing multiple neuroendocrine transmitters [21,23],
and 4) regulating hormonal and serotonin pathway
effects within the CNS [24,25].
Race, ethnicity, dietary intake and sunlight exposure
Dietary intake and sunlight exposure as sources of vita-
min D are influenced by race. The NHANES found poor
dietary intake of vitamin D and lower exercise in older
African American and female Hispanic adolescents.
Although not fully comparable due to different method-
ologies, our mentally ill non-Caucasian population also
demonstrates more vitamin D deficiency, and for Asians
and biracial subjects a greater rate of psychosis, but not
after adjusting for vitamin D level. Small clinical studies
to date suggest potential for a causal link between low
vitamin D and mood disorders [8-11,16,26], necessitating
that randomized controlled trials in carefully defined
populations of interest be performed to better
characterize the relationship between vitamin D defi-
ciency and risk for depression and psychosis.
Alternate hypotheses
In addition to the possibility that vitamin D deficiency
contributes to vulnerability to psychosis, other nutri-
tional factors may play a role: adolescents eating a diet
low in dairy products may also consume less of other
nutrient-rich foods, including those with essential fatty
acids. Adverse omega-3:omega-6 fatty acid ratios and/or
other dietary micronutrient deficiencies that are com-
monly associated with vitamin D deficiency such as
vitamin B12 may also contribute to emergence of psych-
otic symptoms.
Implications for future research in psychiatry
Effects on mental illness
If a prospective association between psychotic
features and vitamin D deficiency is confirmed,
outstanding issues include: 1) how vitamin D affects
monoamine function and the HPA axis and immune
responses to stress and symptom production, 2)
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incident depression or psychosis and their recur-
rence, and 3) whether supplementation improves
symptoms in those with clinically diagnosed depres-
sion or psychosis, especially in populations with
darker skin [26]. An open-label Swedish case-series
suggests that depression is improved by vitamin D
supplementation in adolescents [27]. Prevention stud-
ies in high-risk offspring would be highly novel.
Thus, future studies could target both prevention of
mental and comorbid physical illness, focusing on
disparity and somatic treatment augmentation.
Importance to overall health in psychiatric populations
Normalizing vitamin D levels warrants study in those
with severe mental illness to determine whether, and at
what dose, vitamin D helps protect against metabolic
side effects from psychopharmacologic treatment or
reduces the development of comorbid physical illnesses
such as diabetes, cardiovascular disease, and osteopor-
osis. Low vitamin D is associated with greater BMI, insu-
lin resistance, and systolic blood pressure, lower HDL-C
in obese adolescents and adults, and lower final height in
young adult women [3,28-31]. Vitamin D status may be
especially important in those with serious mental illness
as they develop poorer metabolic health at earlier ages.
Optimal vitamin D levels also may protect against several
different cancers (breast, colon, pancreas, and prostate),
and autoimmune disorders (lupus, multiple sclerosis,
and Type I diabetes) [32]. Molecular mechanisms of vita-
min D that are protective against cancer include redu-
cing cellular oxidative stress [33]. Vitamin D
supplementation may thus represent a low-cost popula-
tion-based intervention capable of reducing utilization of
more intensive physical and mental health treatments;
multiple trials are underway assessing impact on a var-
iety of physical health conditions including osteoporosis,
insulin resistance, and cardiovascular risk. A large scale
epidemiologic RCT (the Vitamin D and omega¬3 Trial;
VITAL) is examining whether supplementation prevents
chronic diseases (www.vitalstudy.org).
Supplementation issues in adolescents
How should low vitamin D levels be corrected? Supple-
mentation with over-the-counter or prescription vitamin
D for those with low vitamin D is important, as natural
dietary sources are few and include chiefly oily fish, irra-
diated mushrooms, egg yolks, and fortified milk, juices,
cereal, and margarine (http://dietary¬supplements.info.
nih.gov/factsheets/vitamind.asp). Most adolescents, espe-
cially those who skip breakfast or are lactose intolerant,
do not consume adequate amounts of these foods to
maintain optimal vitamin D levels, and cannot meet their
requirements through diet alone. Risk for developingvitamin D toxicity with supplements has been largely un-
supported [34]; studies giving as much as 14,000 IU per
week of D3 to adolescents over one year’s time have
shown no evidence of toxicity [35]. A serum level of more
than 200 ng/ml 25-OHD may be necessary for symptoms
of toxicity to occur. The Institute of Medicine in 2010
raised its daily intake recommendations based on evi-
dence for skeletal growth and maintenance; the current
recommended dietary allowance (RDA) is 600 IU per day
for 1–70 years of age with an upper level intake of
4,000 IU per day [36]. The American Academy of
Pediatrics had previously raised its recommended supple-
mentation from 200 IU in 2003 to 400 IU per day in 2008
to prevent rickets in children and adolescents who do not
obtain this goal through fortified foods [37]. Additional
initial supplementation to return deficient individuals to
normal may be indicated as dietary reference intake
amounts recommended by the IOM may still be insuffi-
cient for bone health maintenance in many individuals
[38]. The amount necessary to prevent breast and colon
cancer, Type I diabetes, and multiple sclerosis has been
speculated to be closer to 4,000-8,000 IU per day [32].
The amount appropriate for maintenance of best mental
and physical health is therefore controversial, and is un-
known in the chronically mentally ill, who may
metabolize vitamin D more quickly due to added
oxidative stress burden.
Limitations
This work is limited by a small sample size, cross-sectional
method, inpatient sampling bias, and lack of formal re-
search measures for diagnosis and severity of illness, fam-
ily psychiatric history, sun exposure, and intake of Vitamin
D and other dietary nutrients. No adolescents, however,
were taking vitamin D supplementation. A winter sam-
pling bias is present, potentially contributing to low
rates of D-deficiency, however, this does not rule out
that seasonal effects in illness severity and admission
rates related to greater vitamin D deficiency may occur.
Analysis of ultraviolet radiation for latitudes 0 to 80
degrees N found that for March through October, sites
from 18 degrees to 44 degrees N (the majority of the
continental United States) had equal amounts of vitamin
D producing ultraviolet light; November through Febru-
ary only demonstrated decreases in vitamin D producing
ultraviolet light [39]. Additional limitations include that
adolescents were not screened for osteomalacia; serum
parathyroid hormone values were not routinely checked
in those who were D-deficient; however, several per-
formed clinically were within normal ranges. Many con-
fidence intervals are wide; confirmation of these results
awaits a large sample study and more rigorous design.
Probing smaller enriched clinical samples may be useful
in providing biologic signals of relevance in populations
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Descriptive differences in a clinical population compared
with population norms may also provide direction for fur-
ther investigation related to both interactive effects of
mental illness and ancestry.Conclusion
Vitamin D deficiency is highly prevalent in this descrip-
tive sample of acutely mentally ill adolescents, especially
in African-American and Asian teens, and appears
related to psychotic symptoms. This work is the first to
report an association between psychosis and vitamin D
deficiency in psychiatrically hospitalized adolescents [40]
and confirms this association found previously in an
adult population [13]. Our study also expands on similar
deficiency findings from a Parisian inpatient adolescent
cohort [15], providing clinical diagnoses of mood disor-
ders in the great majority of inpatient teens with vitamin
D deficiency, and further, finding lower risk for psychosis
in the presence of antidepressant treatment. Both
support the possibility that heightened vulnerability to
psychotic features occurs in the substantial proportion of
teens with mood disorders who are vitamin D deficient.
Prospective trials of vitamin D supplementation are
needed to address targeted mental health symptom
domains as well as metabolic health variables in D-defi-
cient severely mentally ill adolescents and adults, focus-
ing on dose-finding and tolerability. Calls have been
made for clinical monitoring in patients with psychiatric
illness as well as randomized trials of vitamin D for
depression [41,42]. Clinical screening for vitamin D
deficiency in severely mentally ill adolescents is justified
by their high risk for both chronic mental illness and
early onset of cardiometabolic comorbidities, especially
as vitamin D deficiency at mid-life appears a strong inde-
pendent predictor of all-cause mortality (odds ratios
2.64, 95% CI 1.901 to 3.662. p< 0.0001) [43]. A key
clinical question raised by our work and supported by
known safety data is whether psychiatrically hospitalized
dark-complected adolescents, including African-Americans,
Asians, and Muslim females in traditional covered dress,
should be routinely supplemented with vitamin D until
proven otherwise.
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